Chemomab Therapeutics (CMMB) EPS (Basic) (2017 - 2025)
Chemomab Therapeutics' (CMMB) quarterly EPS (Basic) came in at $1226.3 in Q4 2025, up 366.99% YoY from $262.59 in Q4 2024, and up 34798761.8% on a QoQ basis from $0.0 in Q3 2025.
Chemomab Therapeutics (CMMB) EPS (Basic) (2017 - 2025) Analysis & Trends
Chemomab Therapeutics (CMMB) has 9 years of EPS (Basic) data on file, last reported at $1226.3 in Q4 2025.
- Quarterly EPS (Basic) rose 366.99% year-over-year to $1226.3 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1226.3 (up 366.98% YoY) and the FY2025 annual result came in at -$0.02, down 81.56% from the prior year.
- EPS (Basic) rose to $1226.3 in Q4 2025, from $0.0 in the prior quarter.
- In the past five years, EPS (Basic) ranged from a high of $1226.3 in Q4 2025 to a low of -$0.01 in Q4 2021.
- A 5-year average of $99.26 and a median of $0.0 in 2023 frame the typical range for EPS (Basic).
- Annual changes were most pronounced in 2022 — EPS (Basic) plunged 105.85% — and 2024, when it surged 7223623.74%.
- Tracing CMMB's EPS (Basic) over 5 years: stood at -$0.01 in 2021, then surged by 249.37% to $0.01 in 2022, then plunged by 59.9% to $0.0 in 2023, then surged by 7223623.74% to $262.59 in 2024, then surged by 366.99% to $1226.3 in 2025.
- The last three EPS (Basic) figures came in at $1226.3 (Q4 2025), $0.0 (Q3 2025), and $262.59 (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.84 Bn | 131.99 Bn | 2.84 Bn | 4.34 |
| 2 | Regeneron Pharmaceuticals | 86.48 Bn | 78.49 Bn | 3.93 Bn | 12.62 |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn | 7.59 |
| 4 | Moderna | 60.15 Bn | 55.01 Bn | 52.00 Mn | -1.96 |
| 5 | BeOne Medicines | 42.22 Bn | 37.12 Bn | 1.53 Bn | 2.12 |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | 1.23 |
| 7 | BioNTech SE | 28.54 Bn | 10.14 Bn | 668.28 Mn | -0.72 |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | -0.06 |
| 9 | Royalty Pharma | 27.22 Bn | 26.38 Bn | - | 0.18 |
| 10 | Chemomab Therapeutics | 13.30 Mn | 2.93 Mn | - | 0.29 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1,226.28 |
| Sep 30, 2025 | 0.00 |
| Dec 31, 2024 | 262.59 |
| Sep 30, 2024 | 0.01 |
| Mar 31, 2024 | 0.00 |
| Dec 31, 2023 | 0.00 |
| Sep 30, 2023 | 0.00 |
| Mar 31, 2023 | 0.01 |
| Dec 31, 2022 | 0.01 |
| Sep 30, 2022 | 0.01 |
| Mar 31, 2022 | -0.01 |
| Dec 31, 2021 | -0.01 |
| Sep 30, 2021 | 0.00 |
| Jun 30, 2021 | 0.00 |
| Mar 31, 2021 | 0.00 |
| Dec 31, 2020 | -10.76 |
| Sep 30, 2020 | 0.00 |
| Jun 30, 2020 | 0.00 |
| Mar 31, 2020 | 0.00 |
| Dec 31, 2019 | -0.12 |